Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways

Pharmaceuticals(2021)10.3390/ph14111122Source: DataRank Database

Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways is a research paper published in Pharmaceuticals (2021). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.41)OA: goldTopics (19)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Sabrina Hafeez,Jessica L. Christenson ORCID,Kathleen O’Neill ORCID,Nia G. Hammond ORCID,Jennifer K. Richer ORCID

Live enrichment

PubMed:34832904 PMC:PMC8622696 OpenAlex:https://openalex.org/W3208076699

National Institutes of Health

Grant: T32CA190216

National Institutes of Health

Grant: F32CA239436

United States Department of Defense

Grant: W81XWH-15-1-0039

United States Department of Defense

Grant: W81XWH-19-BCRP-EA

FWCI

0.41

Citation Percentile

0.6%

Citation Trend

2022

2023

2025

goldLicense: cc-by

journalhttps://www.mdpi.com/1424-8247/14/11/1122/pdf?version=1635845460

publisherhttps://www.mdpi.com/1424-8247/14/11/1122/pdf?version=1635845460

publisherhttps://www.mdpi.com/1424-8247/14/11/1122/pdf

journalhttps://doi.org/10.3390/ph14111122

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34832904

Fields of Study

Cancer Immunotherapy and BiomarkersCancer Cells and MetastasisEpigenetics and DNA Methylation

Keywords

ImmunotherapyTriple-negative breast cancerMedicineImmune systemImmune checkpointCancer researchBreast cancerEpithelial–mesenchymal transitionCancerOncologyImmunologyInternal medicineMetastasisimmune suppressionTriple Negative Breast CancerEpithelial-to-mesenchymal Transition

Sustainable Development Goals

SDG 0: Good health and well-being